Xinghua Lu
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Cancer is mainly caused by a relatively small portion of somatic genome alterations (SGAs), called cancer drivers. Despite success in identifying a good number of cancer drivers, many more remain to be discovered to explain various cancers. Moreover, limited tools are available to identify potential interactions among cancer drivers for a better understanding of oncogenesis. To tackle these challenges, we have developed a novel approach called individualized Bayesian inference using a decision tree (IBI-DT). IBI-DT recognizes the genetic heterogeneity among cancer patients, where different individuals or patient subgroups of distinct genomic makeup may have different drivers. IBI-DT works by constructing smaller subgroups with similar genetic makeup (i.e. patient-like-me subgroups) using a decision tree structure and analyzing multiple trees to identify the SGAs that play a significant role in regulating downstream gene expression patterns at the subgroup and individual levels. This is distinct from population-based approaches, which tend to evaluate the influence of an SGA for the entire population, thereby likely missing low-frequency SGAs that may well explain a small subgroup of cancer patients. Also importantly, IBI-DT can efficiently identify cancer drivers that may have functional interactions. We applied IBI-DT to identify cancer drivers regulating the downstream differential gene expression in cancer patients and compared it to the standard, population-based method of expression quantitative trait loci analysis. Our results show that IBI-DT performs well in identifying both important cancer drivers, especially the low-frequency drivers, and their interactions, allowing for a better understanding of the cancer signaling pathways.
Year:
2025
Background Immune checkpoint blockade (ICB) targeting PD-1/PD-L1 plays a crucial role in breast cancer treatment. Despite clinical success, how ICB reshapes the tumor microenvironment (TME) to enhance anti-tumor activity remains unclear. Anti-PD-1 therapy alters TME cells beyond PD-1+ T cells, with extensive cell-cell communication (CCC) playing a key role. Understanding the dynamic CCC changes upon anti-PD-1 treatment can illuminate ICB mechanisms of action and TME dynamics. Methods We analyzed single-cell RNA-seq data from 31 breast cancer patients before and after anti-PD-1 (pembrolizumab) treatment (Bassez et al., 2021). We identified differentially expressed genes (DEGs) induced by treatment in major cell types. We then applied an instrumental variable approach to uncover causal relationships between T-cell and non-T-cell DEGs. We further mapped ligand-receptor interactions mediating signal transduction between cells and constructed a CCC network from T to non-T cells. Results Anti-PD-1 therapy induced widespread transcriptional changes across multiple cell populations. Key pathways modulated in T cells included NF-κB, interferon-γ, and interleukin signaling. CD4+ and CD8+ exhausted T cells engaged in distinct ligand-receptor interactions with tumor-associated macrophages (TAMs) and other types of cells, reshaping the TME. Our results indicated CD4+ exhausted T cells activated M1-like TAMs via TNF-TNFRSF1A and TNFSF14-LTBR, while CD8+ exhausted T cells engaged M1-like TAMs through ICAM1-ITGAL/ITGB2 and CCL8-CCR2, promoting anti-tumor immunity. Conversely, immunosuppressive interactions were also observed, such as TNF–TNFRSF1B (TNFR2) and TNFSF14–TNFRSF14 (HVEM) from CD4⁺ T cells, as well as CSF1–CSF1R and RPS19–C5AR1 from CD8⁺ T cells, which likely promote M2-like tumor-associated macrophage (TAM) polarization and contribute to pro-tumor immune regulation and resistance to therapy. Notably, key receptors in the causal CCC networks, such as C5AR1, TNFR2, and CSF1R, emerged as potential targets to enhance anti-PD-1 efficacy. Conclusions These findings elucidate TME remodeling during anti-PD-1 therapy and underscore the pivotal role of CCC in treatment response. Our study identifies critical communication networks that may be biomarkers for immunotherapy responsiveness and highlights novel therapeutic targets, including C5AR1 and HVEM. Furthermore, our application of causal inference methodologies provides a robust framework for dissecting CCC mechanisms in immunotherapy.
Year:
2025
Understanding tumor heterogeneity at the resolution of individualized cell–cell communication networks (CCCNs) remains a major computational challenge in precision oncology. Existing inference methods largely rely on population-level correlation and thus fail to capture patient-specific signaling patterns across diverse cell types. To address this limitation, we developed an integrative computational framework combining the nested hierarchical Dirichlet process (nHDP) model for identifying hierarchically structured gene expression modules, with instance-specific Greedy Fast Causal Inference (iGFCI) for inferring individualized CCCNs (iCCCNs) in colorectal cancer (CRC). Applied to large-scale single-cell RNA-seq data from over 625,000 cells, our model successfully decomposed complex gene expression modules GEMs, potentially representing the cell lineage and cellular signaling states, and uncovered iCCCNs across detailed cell subtypes. We further used TCGA bulk RNA-seq data with survival data to validate the clinical relevance of these individualized gene expression module causal interactions, demonstrating their potential as robust prognostic signatures in CRC. Finally, we used principled causal inference methods to search for ligand-receptor pairs that mediate cell-cell communication. This framework enables mechanistic insights into immune evasion. Our computational method represents a significant advance toward realizing personalized oncology, enabling precise patient stratification and identification of actionable biomarkers for improved therapeutic targeting in cancers.
Year:
2025
Cells within a tissue microenvironment communicate through intricate cell-cell communication (CCC) networks. In this meta-analysis of eight single-cell cohorts encompassing 153 patients and 279 samples, we advance the understanding of CCC networks in colorectal cancers through a novel analytical framework. Employing hierarchical topic modeling, we identify gene expression modules (GEMs) that mirror single-cell signaling states, crucial for deciphering the complexity of intercellular interactions. By applying causal discovery methods, we systematically uncover GEMs likely regulated by ligand-receptor signaling and cross-cell-type communication. This analysis reveals cross-cell-type CCC programs, marked by highly correlated GEMs across various cell types, shedding light on the intricate CCC networks within the tumor microenvironment. Spatial transcriptomics further validate these findings by demonstrating the co-localization of GEMs within CCC programs in distinct spatial domains, emphasizing the spatial dynamics of tumor intercellular communication. Our interactive website ( http://44.192.10.166:3838/ ) and analytical framework equip researchers with powerful tools to explore these complex mechanisms, potentially uncovering novel drug targets and refining strategies for precision immunotherapies. This comprehensive study not only presents a detailed catalog of CCC networks driven by ligand-receptor interactions in colorectal cancer but also highlights the significance of integrating multi-sample and patient data to unravel the molecular underpinnings of cancer communication pathways.
Year:
2025
Immune checkpoint blockade (ICB) has revolutionized the current immuno-oncology and significantly improved clinical outcome for cancer treatment. Despite the advancement in clinics, only a small subset of patients derives immune response to the ICB therapy. Therefore, a robust predictive biomarker that identifies potential candidate becomes increasingly crucial in delivering this technology to the public. In this review, we first discuss the biomarkers that focus on tumor genome, tumor microenvironment and tumor-host interaction. Then, we compare existing databases for biomarker discovery for ICB response. We also present IOhub - an interactive web portal that incorporates 36 bulk and 10 single-cell transcriptome datasets for benchmark analysis of the current biomarkers. Finally, we highlight the trending interest in antibody drug conjugate and combination treatment and their use in precision immuno-oncology.
Year:
2024
BRAFV600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAFV600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also trigger tumor suppression. Whether and how oncogenic ERK signaling can be intrinsically adjusted to a “just-right” level optimal for tumorigenesis remains undetermined. In this study, we found that FAK (Focal adhesion kinase) expression was reduced in BRAFV600E-mutant adenomas/polyps in mice and patients. In Vill-Cre;BRAFV600E/+;Fakfl/fl mice, Fak deletion maximized BRAFV600E’s oncogenic activity and increased cecal tumor incidence to 100%. Mechanistically, our results showed that Fak loss, without jeopardizing BRAFV600E-induced ERK pathway transcriptional output, reduced EGFR (epidermal growth factor receptor)-dependent ERK phosphorylation. Reduction in ERK phosphorylation resulted in increased mRNA expression and stability of Lgr4, promoting intestinal stemness and cecal tumor formation. Together, our findings show that a “just-right” ERK signaling optimal for BRAFV600E-induced cecal tumor formation can be achieved via Fak loss-mediated downregulation of ERK phosphorylation.
Year:
2024
BRAF V600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAF V600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also trigger tumor suppression. Whether and how oncogenic ERK signaling can be intrinsically adjusted to a ‘just-right’ level optimal for tumorigenesis remains undetermined. In this study, we found that FAK (Focal adhesion kinase) expression was reduced in BRAF V600E -mutant adenomas/polyps in mice and patients. In Vil1-Cre;BRAF LSL-V600E/+ ; Ptk2 fl/fl mice, Fak deletion maximized BRAF V600E ’s oncogenic activity and increased cecal tumor incidence to 100%. Mechanistically, our results showed that Fak loss, without jeopardizing BRAF V600E -induced ERK pathway transcriptional output, reduced EGFR (epidermal growth factor receptor)-dependent ERK phosphorylation. Reduction in ERK phosphorylation increased the level of Lgr4, promoting intestinal stemness and cecal tumor formation. Our findings show that a ‘just-right’ ERK signaling optimal for BRAF V600E -induced cecal tumor formation can be achieved via Fak loss-mediated downregulation of ERK phosphorylation.
Year:
2024
BRAF V600E mutation is a driver mutation in the serrated pathway to colorectal cancers. BRAF V600E drives tumorigenesis through constitutive downstream extracellular signal-regulated kinase (ERK) activation, but high-intensity ERK activation can also trigger tumor suppression. Whether and how oncogenic ERK signaling can be intrinsically adjusted to a "just-right" level optimal for tumorigenesis remains undetermined. In this study, we found that FAK (Focal adhesion kinase) expression was reduced in BRAF V600E -mutant adenomas/polyps in mice and patients. In Vill-Cre ; BRAF V600E/+ ; Fak fl/fl mice, Fak deletion maximized BRAF V600E 's oncogenic activity and increased cecal tumor incidence to 100%. Mechanistically, our results showed that Fak loss, without jeopardizing BRAF V600E -induced ERK pathway transcriptional output, reduced EGFR (epidermal growth factor receptor)-dependent ERK phosphorylation. Reduction in ERK phosphorylation increased the level of Lgr4, promoting intestinal stemness and cecal tumor formation. Our findings show that a "just-right" ERK signaling optimal for BRAF V600E -induced cecal tumor formation can be achieved via Fak loss-mediated downregulation of ERK phosphorylation.
Year:
2024
Collaborators (4)
Jing Wang
Professor
-
Jinling Liu
Assistant Professor and Principal Investigator
University of Florida
Farzad Esni
Associate Professor
University of Pittsburgh
Jing Hu
Associate Professor
University of Pittsburgh
Make your next move.
Prepare your application
Review drafts before you send them.